United Therapeutics Tyvaso DPI — Total revenues decreased by 2.5% to $330.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.2%, from $302.50M to $330.30M. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates growing market demand or successful commercial penetration, while a decrease may signal market saturation, increased competition, or loss of patent exclusivity.
Represents the total gross revenue generated from the sale of a specific pharmaceutical product or therapeutic line with...
Standard revenue reporting for specific drug franchises or product lines across pharmaceutical peers.
uthr_segment_tyvaso_dpi_total_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $63.10M | $118.70M | $193.60M | $205.10M | $213.70M | $227.50M | $258.30M | $274.60M | $273.20M | $302.50M | $315.20M | $336.20M | $338.60M | $330.30M |
| QoQ Change | — | — | — | — | +88.1% | +63.1% | +5.9% | +4.2% | +6.5% | +13.5% | +6.3% | -0.5% | +10.7% | +4.2% | +6.7% | +0.7% | -2.5% |
| YoY Change | — | — | — | — | — | — | +225.0% | — | +91.7% | +33.4% | +33.9% | +27.8% | +33.0% | +22.0% | +22.4% | +23.9% | +9.2% |